ERBB2 and breast carcinoma: EphA5, a member of Eph receptors, has been implicated in various biological activities, including tumorigenesis and progression of different cancers [6–10], radioresistance in lung cancer [11] and sensitivity to trastuzumab in HER2-positive breast cancer [12].